Advaxis Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Advaxis Contact Number

Advaxis Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Show details

609-452-9813

Company Type For Profit. Contact Email [email protected]advaxis.com. Phone Number 609-452-9813. Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to

Founded: 2002
Founder: Yvonne Paterson

Category: Contact NumberShow more

Advaxis, Inc. Biotechnology Company Princeton, New

2 hours ago Facebook.com Show details

Advaxis, Inc., Princeton, New Jersey. 593 likes · 3 talking about this · 13 were here. Advaxis is a clinical-stage biotechnology company

Rating: 4.1/5
Location: 305 College Rd E, Princeton, NJ, 08540, New Jersey

Category: Tech SupportShow more

Advaxis Inc (ADXS) Quote XNAS Morningstar

Just Now Morningstar.com Show details

609 452-9813

Contact 305 College Road East Princeton, NJ, 8540. T +1 609 452-9813. www.advaxis.com Sector Healthcare. Industry Biotechnology. Most Recent Earnings Jul 31, 2021. Fiscal Year End Oct 31, 2021.

Employees: 18

Category: Contact NumberShow more

Advaxis, Inc. LinkedIn

5 hours ago Linkedin.com Show details

Advaxis, Inc. 3,713 followers on LinkedIn. Advaxis (NASDAQ: ADXS) is a late -stage biotechnology company developing multiple cancer immunotherapies based on …

Founded: 2002

Category: Contact NumberShow more

Advaxis, Inc. (ADXS) Company Profile & Facts Yahoo Finance

4 hours ago Finance.yahoo.com Show details

See the company profile for Advaxis, Inc. (ADXS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key …

Category: Contact NumberShow more

Advaxis, Inc. (Form: PRE 14A, Received: 04/02/2021 16:16:18)

3 hours ago Marketwatch.com Show details

(1) The Advaxis, Inc. 2015 Incentive Plan includes an “evergreen” provision, under which the aggregate number of shares of common stock reserved and available for issuance pursuant to …

Category: Contact NumberShow more

Jobs with Advaxis, Inc. BioSpace

4 hours ago Biospace.com Show details

Advaxis, Inc. Announces Closing of $9.2 Million Public Offering. 11/27/2020. PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an …

Category: Contact NumberShow more

Advaxis, Inc. Adopts Limited Duration Stockholder Rights

8 hours ago Nasdaq.com Show details

--Advaxis, Inc., a clinical-stage a number of shares of Advaxis’ common stock having a market value of twice such price. Contact Tim McCarthy, LifeSci Advisors,

Category: Contact NumberShow more

Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan

4 hours ago Ca.finance.yahoo.com Show details

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend …

Category: Contact NumberShow more

Advaxis’ Axalimogene Filolisbac to be Developed and

1 hours ago Money.cnn.com Show details

These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC …

Category: Contact NumberShow more

Advaxis Wikipedia

8 hours ago En.wikipedia.org Show details

Advaxis Inc. is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm).: 1 The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.: 1 The Lm-based platform on which the company's …

Category: Contact NumberShow more

INVESTIGATION: Halper Sadeh LLP Investigates LONE, KIN

9 hours ago Finance.yahoo.com Show details

Advaxis, Inc. (NASDAQ:ADXS) Shareholders are encouraged to contact the firm free of charge to discuss their legal rights While Ma made a limited number of public appearances in mainland

Category: Contact NumberShow more

ADXS Advaxis Inc. Stock Price & News WSJ

3 hours ago Wsj.com Show details

News Advaxis Inc.ADXS. No news for in the past two years. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by …

Category: Contact NumberShow more

ADXS Company Profile for ADVAXIS, INC. MSN Money

1 hours ago Msn.com Show details

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies.

Category: Contact NumberShow more

Advaxis Inc Company Profile and News Bloomberg Markets

9 hours ago Bloomberg.com Show details

Company profile page for Advaxis Inc including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

Working At Advaxis Zippia

3 hours ago Zippia.com Show details

Advaxis is a small pharmaceutical company based in New Jersey with only 90 employees and an annual revenue of $11.0M. The Organization’s Mission. To develop cancer immunotherapies that teach the body to recognize tumors as a threat and do so in a way that minimizes side effects associated with traditional chemotherapy and radiation. Industry.

Category: Contact NumberShow more

Advaxis Funding, Financials, Valuation & Investors

Just Now Crunchbase.com Show details

Funding. Advaxis has raised a total of $148.5M in funding over 11 rounds. Their latest funding was raised on Apr 12, 2021 from a Post-IPO Equity round. Advaxis is registered under the ticker NASDAQ:ADXS . Advaxis is funded by 10 investors. Cantor Fitzgerald and Jefferies are the most recent investors.

Category: Contact NumberShow more

Advaxis, Inc. (ADXS) company profile & facts – Yahoo Finance

4 hours ago Uk.finance.yahoo.com Show details

See the company profile for Advaxis, Inc. (ADXS), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information.

Category: Contact NumberShow more

Advaxis Merger Investigation: Halper Sadeh LLP Announces

Just Now Sg.finance.yahoo.com Show details

(212) 763-0060

Halper Sadeh encourages Advaxis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected] Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Category: Contact NumberShow more

Advaxis to Present at the NonSmall Cell Lung Cancer Drug

9 hours ago Sg.finance.yahoo.com Show details

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer of Advaxis, will present data from Part B …

Category: Cell PhoneShow more

Working at Advaxis Glassdoor

5 hours ago Glassdoor.com Show details

I applied through a staffing agency. The process took 3 days. I interviewed at Advaxis (United States) Typical interview process. Interviewed by five people in a round robin kind of format. Very informal. Friendly vibes. You get a feel for the different roles and leadership styles of each supervisor or manager, which is helpful.

Category: Contact NumberShow more

Amid troubles, exRosetta CEO Berlin parachuted in as new

2 hours ago Fiercebiotech.com Show details

Amid troubles, ex-Rosetta CEO Berlin parachuted in as new Advaxis head. Advaxis' former CEO, Daniel O'Connor, left abruptly last July and CBO Tony Lombardi stepped in as interim CEO for nearly 10

Category: Contact NumberShow more

Daniel J. O’Connor, President and Chief Executive Officer

1 hours ago Money.cnn.com Show details

609.250.7515

CONTACTS: Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO [email protected]advaxis.com 609.250.7515 Media Contact: JPA Health Communications Catherine Brady [email protected] 617.945.9316

Category: Contact NumberShow more

Here’s Our Rant About Advaxis Inc. (ADXS) – News Heater

2 hours ago Newsheater.com Show details

Advaxis Inc. (NASDAQ:ADXS) went up by 5.12% from its latest closing price compared to the recent 1-year high of $1.57. The company’s stock price has collected -7.34% of loss in the last five trading sessions. Press Release reported 16 hours ago that Arbutus Appoints Lisa M. Caperelli as Vice Presi

Category: Contact NumberShow more

Advaxis, Inc. Adopts Limited Duration Stockholder Rights

2 hours ago Biospace.com Show details

In addition, if Advaxis is acquired in a merger or other business combination after an acquiring person acquires 10% or more of Advaxis’ common stock, each holder of the right would thereafter have the right to purchase, upon payment of the exercise price and in accordance with the terms of the rights plan, a number of shares of common stock

Category: Contact NumberShow more

Advaxis (ADXS):New Early Stage Pipeline Offers Significant

Just Now Seekingalpha.com Show details

Advaxis, Inc. is a small clinical-stage biotech developing oncological therapeutics. The author projects ADXS stock as a "hold" with a risky 2-3 year price target of $2.25. Here's why.

Category: Contact NumberShow more

Advaxis, Inc. Announces Pricing of $10.5 Million

4 hours ago Bloomberg.com Show details

212.915.2564

Contact: Tim McCarthy, LifeSci Advisors, LLC 212.915.2564 [email protected] advaxis-squarelogo-1498831554460.png Have a confidential tip for our reporters? GET IN TOUCH

Category: Contact NumberShow more

Advaxis, Inc. Appoints David J. Mauro, M.D., Ph.D., As

6 hours ago Fiercebiotech.com Show details

609.452.9813

CONTACT: Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO [email protected] 609.452.9813 ext. 102 Investors & Media: MDB Communications LLC Michael Becker, President [email

Category: Contact NumberShow more

Advaxis Inc. (ADXS) Investors To Make Money Again

8 hours ago Marketingsentinel.com Show details

Advaxis Inc. (NASDAQ:ADXS)’s Major holders. Insiders own 0.07% of the company shares, while shares held by institutions stand at 11.37% with a share float percentage of 11.38%. Investors are also buoyed by the number of investors in a company, with Advaxis Inc. having a total of 44 institutions that hold shares in the company.

Category: Contact NumberShow more

Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial

2 hours ago Ca.finance.yahoo.com Show details

Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies Initiated Phase 1 clinical trial of ADXS-504 for the treatment of early prostate cancer ADXS-503 Phase 1/2 data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit …

Category: Contact NumberShow more

Advaxis Total Employees (Annual) ADXS

6 hours ago Ycharts.com Show details

Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd. Yahoo 08/11 08:00 ET INVESTIGATION: Halper Sadeh LLP Investigates LONE, KIN, GRA, ADXS; Shareholders are Encouraged to Contact the Firm

Category: Contact NumberShow more

ADXS Stock Price Advaxis Inc. Stock Quote (U.S.: Nasdaq

8 hours ago Marketwatch.com Show details

Advaxis stock drops 14% after company says midstage trial was interrupted by clinical hold Oct. 24, 2016 at 8:13 a.m. ET by Emma Court Bull trend intact, latest S&P 500 breakout attempt underway

Category: Contact NumberShow more

Advaxis Announces Business and Pipeline Update

9 hours ago Businesswire.com Show details

Advaxis Announces Business and Pipeline Update. Cash balance anticipated to extend into 2021. October 24, 2019 09:00 AM Eastern Daylight Time. PRINCETON, N.J.-- ( BUSINESS WIRE )--Advaxis, Inc

Category: Contact NumberShow more

Advaxis Inc. (NASDAQ:ADXS) Is Up 11.31% Over The Past 30

1 hours ago Marketingsentinel.com Show details

Investors also watch the number of corporate investors in a company very closely, which is 11.37% institutions for Advaxis Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at ADXS for having 5.75 million shares of worth $2.67 million.

Category: Contact NumberShow more

Advaxis Inc. (ADXS) Outlook: A Retrospective – Stocks Register

9 hours ago Stocksregister.com Show details

Having a second look at Advaxis Inc. (NASDAQ:ADXS) provides that stock’s average daily trading volume for 3 months was 6.85 million. Number of outstanding shares of the stock stood at 123.14 million. >> 7 Top Picks for the Post-Pandemic Economy

Category: Contact NumberShow more

Working at Advaxis: Employee Reviews Indeed.com

2 hours ago Indeed.com Show details

Advaxis has a lot of potential but the current financial situation makes it difficult to provide a positive work environment. Multiple layoffs have led to people being very fearful of losing their job. Until the financial situation changes, the culture will be challenging.

Rating: 2.7/5(7)

Category: Contact NumberShow more

TKL Research LinkedIn

5 hours ago Linkedin.com Show details

TKL Research 3,865 followers on LinkedIn. Our structure is uncommon. Our level of expertise is rare. We are unique. TKL Research is not your average CRO. …

Category: Contact NumberShow more

Advaxis Inc. (NASDAQ: ADXS) Stock Is A Good Option To

7 hours ago Stocksregister.com Show details

According to the data, the short interest in Advaxis Inc. (ADXS) stood at 3.08% of shares outstanding as of Aug 12, 2021; the number of short shares registered in Jul 14, 2021 reached 4.8 million. The stock has risen by 51.94% since the beginning of the year, thereby showing the potential of a further growth.

Category: Contact NumberShow more

Phase 2 Study of ADXS11001 in Subjects With Carcinoma of

7 hours ago Clinicaltrials.gov Show details

This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 subjects, respectively with persistent/recurrent, loco-regional or metastatic SCCA of the anorectal canal that have received at least 1 regimen for the treatment of advanced disease

Category: Contact NumberShow more

FDA forces troubled Advaxis to halt enrollment on its

2 hours ago Endpts.com Show details

“FDA’s re­view of the AX­AL In­ves­ti­ga­tion­al New Drug (IND) ap­pli­ca­tion was prompt­ed by our pro­pos­al to mod­i­fy the AIM2CERV tri­al’s analy­sis plan to in­clude

Category: Contact NumberShow more

Advaxis Careers & Employment Working at Advaxis Indeed.com

4 hours ago Indeed.com Show details

Advaxis is also hemorrhaging most of its good people. Sr. Clinical Research Associate - In-house in Princeton, NJ. 4.0. on September 20, 2017. Rewarding and educational environment. Advaxis was a great place to work and has great employees to work with. A very friendly environment in the office and has recognition benefits for working hard.

Category: Contact NumberShow more

Advaxis hit with clinical hold for cervical cancer drug

8 hours ago Biopharmadive.com Show details

Dive Insight: The notice is not the first clinical trial challenge for Advaxis and axalimogene filolisbac. In March 2018, the FDA put the drug on a clinical hold after a patient died from respiratory failure in a Phase 1/2 study of the drug with AstraZeneca's Imfinzi (durvalumab) in advanced, recurrent or refractory human papillomavirus-associated cervical cancer and …

Category: Contact NumberShow more

Preliminary Data from Phase 1 Study Evaluating ADXSNEO

7 hours ago Businesswire.com Show details

Advaxis Forward-Looking Statement Some of the statements included in this press release may be forward-looking statements that involve a …

Category: Contact NumberShow more

Advaxis, Inc. 10Q Sep. 9, 2021 9:46 PM Seeking Alpha

9 hours ago Seekingalpha.com Show details

Commission file number 001-36138 . ADVAXIS, INC. (Exact name of registrant as specified in its charter) Delaware : 02-0563870 (State or other jurisdiction of (IRS Employer:

Category: Contact NumberShow more

Can Advaxis Inc. (ADXS) Remain Competitive? – News Heater

6 hours ago Newsheater.com Show details

Advaxis Inc. (NASDAQ:ADXS) went down by -9.38% from its latest closing price compared to the recent 1-year high of $1.57. The company’s stock price has collected -14.23% of loss in the last five trading sessions. Press Release reported on 09/10/21 that Advaxis Reports 3rd Quarter Ended July 31, 20

Category: Contact NumberShow more

An Assessment of an Attenuated Live Listeria Vaccine in

1 hours ago Clinicaltrials.gov Show details

E7 is a substance that is made by the HPV virus which causes cervical cancer. The purpose of the study is to test the safety, tolerability (how the drug makes you feel), immunology (effects on the immune system) and efficacy (disease curing effects) of a vaccine called Lovaxin C against E7. The vaccine is designed to cause the immune system to

Category: Contact NumberShow more

Is Advaxis, Inc. (ADXS) Stock About to Get Hot Monday?

1 hours ago Investorsobserver.com Show details

Advaxis, Inc. (ADXS) stock is down -3.43% while the S&P 500 has risen 0.11% as of 1:09 PM on Monday, Sep 13. ADXS is lower by -$0.02 from the previous closing price of $0.60 on volume of 13,855,216 shares. Over the past year the S&P 500 is higher by 31.92% while ADXS has risen 31.82%. ADXS lost -$0.20 per share in the over the last 12 months.

Category: Contact NumberShow more

Advaxis Reports Fiscal Year 2020 Financial Results and

1 hours ago Apnews.com Show details

Management Commentary “Fiscal year 2020 was transformative for Advaxis, with important clinical and biomarker data from the ongoing Phase 1/2 study of ADXS-503 in NSCLC which now consistently show the potential of ADXS-503 to synergistically enhance and/or restore sensitivity to checkpoint inhibitors,” said Kenneth A. Berlin, President and Chief Executive …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Amazon
Abbvie
Aia
Asml
Amgen
Att
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes